Based on 3 analysts giving stock ratings to Cardiol Therapeutics Inc in the past month.
In the current month, CRDL has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CRDL average Analyst price target in the last month is 8.750.
Based on analysts' estimates, CRDL EPS is projected to reach -0.058 in FY2026Q4, following reported EPS of -0.079 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.08, while Cardiol Therapeutics IncCRDL's earnings per share (EPS) for the previous quarter was USD -0.04. EPS for the next quarter is expected at USD -0.06.